Impact of Psychomotor Therapy on the Quality of Life in Depression
ConditionMajor Depressive Disorder
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age20-60
SponsorCentre Hospitalier Esquirol
About this trial
The effectiveness of psychomotor therapy in improving clinical outcomes or quality of life for individuals with depression is unclear.
The investigators will assess how the participants' quality of life and psychomotor profile change over time.
The study aims to compare the quality of life at 3 months between patients who received 3 months of personalised psychomotor therapy in addition to standard treatment and those who received standard treatment alone.
The study lasted for 6 months, and the investigators expects a total of 128 people to participate in this research across several hospital establishments. This study evaluates the effectiveness of two types of treatment, divided into two randomly selected groups.
To participate, individuals must have a medical diagnosis of major depressive disorder (MDD) and be between the ages of 20 and 60.
They must have depressive symptoms with an HDRS score greater than 16 and provide informed consent. They must be treated or hospitalised at the Centre Hospitalier Esquirol or the Centre Hospitalier Henri Laborit (France).
After providing consent, they will undergo an initial clinical interview that evaluates anxiety, self-esteem, pleasure, and quality of life. The therapist assessed the participant's muscle tone, gross motor skills, praxis, manual dexterity, rhythm, processing of sensory information, and body image.
Following the assessment, the participant was randomly assigned to either the experimental or control group.
The experimental group received the usual treatment for depression and underwent psychomotor therapy once a week for 12 weeks.
The control group received the standard treatment for depression and underwent weekly telephone interviews.
An assessment is scheduled at 1 month to evaluate the participant's health status, including any changes to treatment and assessment of anxiety and depressive symptoms.
Another interim check-up is scheduled at 3 months to assess the patient's health status. The interview will also assess any changes to treatment, anxiety and depressive symptoms, quality of life, and psychomotor function.
A final visit will be scheduled at 6 months for an assessment of the participant's health. The interview will also assess any changes to treatment, anxiety and depressive symptoms, quality of life, and psychomotor function.
Eligibility criteria
Qualifiers
Diagnosis of depressive episode according to DSM-5 criteria.
HDRS > 16
Hospitalized or followed-up in one of the participating centers.
Affiliated or beneficiary of a social security scheme.
Disqualifiers
Psychiatric comorbidity (non-tobacco addiction, eating disorders, bipolar disorder, obsessive-compulsive disorder, schizophrenia and related disorders)
Sensory impairment or proven neurological pathology
History of neurological brain damage (including stroke, tumor, trauma resulting in loss of consciousness lasting more than 10 minutes)
Limited functional ability (difficulty in moving about, performing manual tasks or moving about)
Trial design
Treatments tested in this trial
- Personalised psychomotor therapy
- Usual treatment
Treatment groups
128 Participants
are divided into 2 treatment groupsSponsors and collaborators
Centre Hospitalier Esquirol
Lead sponsor
Direction Générale de l'Offre de Soins
Collaborator
Source ClinicalTrials.gov